Andromeda Surgical vs Restream
Side-by-side comparison of AI visibility scores, market position, and capabilities
Surgical robotics company achieving world's first robotic-assisted HoLEP for prostate treatment; YC-backed targeting $10B+ urology market with Richard Wolf and Quanta System partnerships.
About
Andromeda Surgical is a surgical robotics company developing autonomous robots for urological procedures — specifically targeting the HoLEP (Holmium Laser Enucleation of the Prostate) procedure used to treat benign prostatic hyperplasia (BPH, enlarged prostate), a condition affecting 50%+ of men over 50. Founded in 2023 by CEO Nick Damiano and CTO Kartik Tiwari and a Y Combinator S23 graduate, Andromeda raised $500,000 in seed funding from CoreNest and YC, and achieved the world's first robotic-assisted HoLEP procedure in December 2024 — a significant clinical milestone.\n\nAndromeda's surgical robot assists urologists performing HoLEP procedures by providing precise laser energy delivery and tissue manipulation, targeting the improvement in procedural consistency and outcome reproducibility that robotic assistance provides across varying surgeon skill levels. HoLEP is considered the gold standard treatment for BPH but has a steep learning curve — it requires 30-50+ procedures to achieve proficiency, limiting its adoption to high-volume academic medical centers. Andromeda's robotic assistance aims to make HoLEP accessible at community hospitals by reducing the expertise barrier.\n\nIn 2025, Andromeda competes in the surgical robotics market with Intuitive Surgical (da Vinci for soft tissue surgery), GYRUS Medical (urological instruments), and emerging robotic surgery startups targeting different procedural niches for surgical automation. The global urology surgery robotics market represents a $3+ billion opportunity, with the broader HoLEP addressable market estimated at $10+ billion. Strategic partnerships with Richard Wolf (endoscopy equipment) and Quanta System (laser platforms) provide Andromeda with established distribution channels and clinical credibility. The 2025 strategy focuses on additional clinical procedures to build the safety evidence required for FDA clearance, expanding from the first-in-human milestone toward a pivotal trial for regulatory submission.
Austin multi-streaming platform broadcasting live video to 30+ destinations including Twitch, YouTube, and Facebook Live simultaneously; trusted by creators, media companies, and businesses.
About
Restream is an Austin-based live streaming company that provides multi-stream broadcasting technology enabling content creators, businesses, and media companies to broadcast live video simultaneously to over 30 streaming destinations including Twitch, YouTube, Facebook Live, LinkedIn Live, and custom RTMP destinations from a single source. The platform eliminates the need to choose a single streaming platform by enabling simultaneous multi-destination broadcasting, maximizing audience reach across wherever viewers are watching. Restream also provides a browser-based live studio for creating professional broadcasts without dedicated streaming hardware, including overlays, lower-thirds, guest invitations, and screen sharing. The company serves a broad range of users from gaming streamers and podcasters to corporate communications teams running product launches and all-hands meetings. Founded in 2015 in Kyiv with operations in Austin, Restream has grown to serve millions of streamers globally. The company raised over $50M from investors including Bessemer Venture Partners and competes with StreamYard, OBS, and Wirecast in the live streaming software market.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.